Dermatology and Venereology Unit, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, SE-17176 Stockholm, Sweden.
Acta Derm Venereol. 2018 Mar 13;98(3):324-328. doi: 10.2340/00015555-2852.
Atopic dermatitis (AD) is a chronic, itchy, inflammatory skin disorder that may worsen due to stress and anxiety. Tachykinins have been suggested to be involved in the inflammation in AD, as well as pruritus. Aprepitant is a NK-1 receptor antagonist. This open randomized trial evaluated the effect of aprepitant added to topical treatment in adult patients with moderate-severe AD. The treatment group (n = 19) received 80 mg/day aprepitant for 7 days as a supplement to standardized topical treatment with a moderately strong steroid and a moisturizer. The control group (n = 20) received topical treatment alone. Patients were monitored for the extent of the disease (using SCORing of Atopic Dermatitis; SCORAD), pruritus, and scratching movements. In both the aprepitant-treated and the control groups there was a decrease in SCORAD, pruritus and scratching movements. However, there was no significant additional improvement in any of these parameters in the aprepitant-treated group compared with the control group.
特应性皮炎（AD）是一种慢性、瘙痒、炎症性皮肤病，可能因压力和焦虑而加重。速激肽被认为参与 AD 的炎症和瘙痒。阿瑞匹坦是一种 NK-1 受体拮抗剂。这项开放性随机试验评估了阿瑞匹坦添加到外用治疗中对中重度 AD 成年患者的影响。治疗组（n=19）接受 80 mg/天阿瑞匹坦治疗 7 天，作为中度强效类固醇和保湿剂标准化外用治疗的补充。对照组（n=20）仅接受外用治疗。监测患者的疾病程度（使用特应性皮炎评分；SCORAD）、瘙痒和搔抓动作。在阿瑞匹坦治疗组和对照组中，SCORAD、瘙痒和搔抓动作均有下降。然而，与对照组相比，阿瑞匹坦治疗组在这些参数中没有任何一个参数有显著的额外改善。
